Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 1/2016

01-02-2016 | Case Report

Colloidal silica-induced hypersensitivity: myth or reality

Authors: Nadia Ben Fredj, Najeh Ben Fadhel, Amel Chaabane, Zohra Chadly, Haifa Ben Romdhane, Abderrazzek Boughattas, Karim Aouam

Published in: International Journal of Clinical Pharmacy | Issue 1/2016

Login to get access

Abstract

Background Many excipients have been reported to induce drug hypersensitivity (e.g. colouring additives, preservatives). Colloidal silica has never been reported to induce drug hypersensitivity reactions. Case report We report herein a 40-year-old patient who developed a skin eruption 2 days after Voltarene® (diclofenac) intake, confirmed by a positive patch test. Investigation of cross reactivity, assessed by patch testing to other non steroidal anti-inflammatory drugs, have showed a positive reaction only to piroxicam (Piroxen®), ketoprofen (Oki®) and indometacin (Indocid®). A hypersensivity to colloidal silica, a common excipient, was suspected. A patch test to this compound was performed showing a positive reaction. Conclusion Colloidal silica, a compound widely used in drug manufacturing, could be another culprit excipient in inducing skin hypersensitivity reactions.
Literature
1.
go back to reference Barbaud A. Place of excipients in systemic drug allergy. Immunol Allergy Clin North Am. 2014;34(3):671–9.CrossRefPubMed Barbaud A. Place of excipients in systemic drug allergy. Immunol Allergy Clin North Am. 2014;34(3):671–9.CrossRefPubMed
2.
go back to reference Rogkakou A, Guerra L, Scordamaglia A, Canonica GW, Passalacqua G. Severe skin reaction due to excipients of an oral iron treatment. Allergy. 2007;62(334–5):16. Rogkakou A, Guerra L, Scordamaglia A, Canonica GW, Passalacqua G. Severe skin reaction due to excipients of an oral iron treatment. Allergy. 2007;62(334–5):16.
3.
go back to reference Zuberbier T, Edenharter G, Worm M, Ehlers I, Reimann S, Hantke T, et al. Prevalence of adverse reactions to food in Germany—a population study. Allergy. 2004;59:338–45.CrossRefPubMed Zuberbier T, Edenharter G, Worm M, Ehlers I, Reimann S, Hantke T, et al. Prevalence of adverse reactions to food in Germany—a population study. Allergy. 2004;59:338–45.CrossRefPubMed
4.
go back to reference Pestana S, Moreira M, Olej B. Safety of ingestion of yellow tartrazine by double blind placebo controlled challenge in 26 atopic adults. Allergol Immunopathol (Madr). 2010;38:142–6.CrossRef Pestana S, Moreira M, Olej B. Safety of ingestion of yellow tartrazine by double blind placebo controlled challenge in 26 atopic adults. Allergol Immunopathol (Madr). 2010;38:142–6.CrossRef
5.
6.
go back to reference Mumoli N, Cei M, Luschi R, Carmignani G, Camaiti A. Allergic reaction to Croscarmellose sodium used as excipient of a generic drug. QJM. 2011;104(8):709–10.CrossRefPubMed Mumoli N, Cei M, Luschi R, Carmignani G, Camaiti A. Allergic reaction to Croscarmellose sodium used as excipient of a generic drug. QJM. 2011;104(8):709–10.CrossRefPubMed
7.
go back to reference Rubinger D, Friedlander M, Superstine E. Hypersensitivity to tablet additives in transplant recipients on prednisone. Lancet. 1978;23:689.CrossRef Rubinger D, Friedlander M, Superstine E. Hypersensitivity to tablet additives in transplant recipients on prednisone. Lancet. 1978;23:689.CrossRef
8.
go back to reference Barbaud A, Waton J, Pinault AL, et al. Cutaneous adverse drug reactions due to delayed sensitization to carboxymethylcellulose. Contact Dermat. 2011;64:294–7.CrossRef Barbaud A, Waton J, Pinault AL, et al. Cutaneous adverse drug reactions due to delayed sensitization to carboxymethylcellulose. Contact Dermat. 2011;64:294–7.CrossRef
9.
go back to reference Swerlick RA, Campbell CF. Medication dyes as a source of drug allergy. J Drugs Dermatol. 2013;12(99–102):15. Swerlick RA, Campbell CF. Medication dyes as a source of drug allergy. J Drugs Dermatol. 2013;12(99–102):15.
10.
go back to reference Alison H, Beverley DG. Pharmaceutical excipients—where do we begin? Aust Prescr. 2011;34:112–4.CrossRef Alison H, Beverley DG. Pharmaceutical excipients—where do we begin? Aust Prescr. 2011;34:112–4.CrossRef
11.
go back to reference Martindale. The complete drug reference, vol. 37. London: Pharmaceutical Press; 2011. Martindale. The complete drug reference, vol. 37. London: Pharmaceutical Press; 2011.
12.
go back to reference Mikkelsen H, Larsen JC, Tarding F. Hypersensitivity reactions to food colours with special reference to the natural colour annatto extract. Arch Toxicol. 1978;1:141–3.CrossRef Mikkelsen H, Larsen JC, Tarding F. Hypersensitivity reactions to food colours with special reference to the natural colour annatto extract. Arch Toxicol. 1978;1:141–3.CrossRef
13.
go back to reference Mori F, Barni S, Pucci N, Maria E, Martino M, Novembre E. Cutaneous adverse reactions to amoxicillin-clavulanic acid suspension in children. Curr Drug Saf. 2012;7:87–91.CrossRefPubMed Mori F, Barni S, Pucci N, Maria E, Martino M, Novembre E. Cutaneous adverse reactions to amoxicillin-clavulanic acid suspension in children. Curr Drug Saf. 2012;7:87–91.CrossRefPubMed
Metadata
Title
Colloidal silica-induced hypersensitivity: myth or reality
Authors
Nadia Ben Fredj
Najeh Ben Fadhel
Amel Chaabane
Zohra Chadly
Haifa Ben Romdhane
Abderrazzek Boughattas
Karim Aouam
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 1/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0225-x

Other articles of this Issue 1/2016

International Journal of Clinical Pharmacy 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine